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Summary 
Nerve growth factor (NGF) induces neurite outgrowth and promotes survival of 
embryonic sensory and sympathetic neurons. TRKA, a receptor tyrosine kinase cloned 
from a human colon cancer was later found to be expressed in the nervous system and 
phosphorylated in response to NGF. Somatic rearrangement(s) of the TRKA gene (also 
designated NTRK1) are responsible for formation of some oncogenes. Genetic defects in 
TRKA are responsible for a human disorder, congenital insensitivity to pain with 
anhidrosis (CIPA). We report here isolation and characterization of the TRKA gene 
which spans at least 23 kb and is split into 17 exons. Exon sizes range from 18 to 394 bp 
and intron sizes range from 170 bp to at least 3.3 kb. Sizes and boundaries of the exons 
were determined, and all the splice donor and acceptor sites conformed to the GT/AG 
rule. Approximately 1.2 kb of the 5’-flanking regions was sequenced, and putative 
regulatory elements were identified. These results will be useful for studies on the 
developmental and biological regulation of the TRKA gene and for further 
characterization of mutations in CIPA patients as well as elucidation of mechanisms 
responsible for rearrangement(s) observed in human tumors. 
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Cell survival, growth and differentiation in nervous systems are mediated by numerous 
growth factors, including neurotrophic factors (neurotrophins). Nerve growth factor (NGF), 
the first neurotrophic factor to be discovered, supports the survival of sympathetic ganglion 
neurons and subpopulations of mainly nociceptive sensory neurons in dorsal root ganglia 
derived from the neural crest as well as ascending cholinergic neurons of the basal forebrain 
(Levi-Montalcini, 1987; Thoenen and Barde, 1980). The TRKA (also named NTRK1) was 
isolated from a colon carcinoma as a potential new member of the tyrosine kinase gene 
family (Martin-Zanca et al., 1986) and was later found to be expressed in the nervous 
system (Martin-Zanca et al., 1990). TRKA is a receptor tyrosine kinase and is 
phosphorylated in response to NGF (Kaplan et al., 1991; Klein et al., 1991). 
Congenital insensitivity to pain with anhidrosis (CIPA; McKusick: 256800, also known 
as congenital sensory neuropathy with anhidrosis, hereditary sensory and autonomic 
neuropathy type IV) is an autosomal-recessive genetic disease characterized by recurrent 
episodes of unexplained fever, anhidrosis (absence of sweating) and absence of reaction to 
noxious stimuli, self-mutilating behavior, and mental retardation (Swanson, 1963; Dyck, 
1984; McKusick, 1994). Recently, we have reported that the gene responsible for CIPA is 
TRKA, suggesting that the NGF-TRKA system plays a crucial role in development and 
function of the nociceptive reception as well as establishment of thermoregulation via 
sweating systems in humans (Indo et al., 1996).  
The TRKA gene is located on the q arm of chromosome 1 (Miozzo et al., 1990; Morris et 
al., 1991). The TRKA -derived oncogenes are also detected in human breast tumor cells 
(Kozma et al., 1988) or in papillary thyroid carcinoma (Butti et al., 1995; Greco et al., 1995). 
These oncogenes are activated by somatic rearrangements juxtaposing their tyrosine kinase 
domain to the 5’-end sequences derived from unrelated loci and producing chimeric 
oncogenes whose products display a constitutive and ectopic tyrosine kinase activity. 
Breakpoints producing some oncogenes often involve a specific region of the TRKA gene 
and part of its sequence has been described (Greco et al., 1993). However, the exact location 
of this region in the whole TRKA gene is unknown, as structure of this gene has not been 
documented. 
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We have now defined the structural and genomic organization of TRKA. This knowledge 
will be useful for studies in developmental and biological regulation of the TRKA gene and 
further characterization of mutation(s) in CIPA patients and as well as elucidation of 
mechanisms responsible for rearrangement(s) of TRKA in human tumors. 
A phage library constructed from human leukocytes (Clontech, Palo Alto, CA) was 
screened to obtain DNA fragments from the TRKA gene. We used a human TRKA cDNA 
(pLM6) (Martin-Zanca et al., 1989) as a radioactively labeled probe and isolated two clones 
(T6 and T11), covering the entire genomic region of TRKA, as shown in Fig. 1. We 
previously characterized the TRKA gene encoding the intracellular domain (Indo et al., 1996). 
In the present study, all the exon/intron splice junctions were determined by comparing the 
human TRKA genomic sequences with the human TRKA cDNA sequences. Size of introns 
was estimated by the sequence of restriction fragments or polymerase chain reaction. The 
human TRKA gene divided into 17 exons ranged in size from 18 bases (exon 9) to 394 bases 
(exon 17), and 16 introns ranged in size from 170 bases (intron 9) to at least 3.3 kb (intron 1). 
The entire human TRKA gene was estimated to span at least 23 kb. The sequences of exon-
intron boundaries are presented in Table 1. All of the splice donor and acceptor sites 
conformed to the GT/AG rule for nucleotides immediately flanking the exon border (Shapiro 
and Senapathy, 1987). 
A single transmembrane domain divides the TRKA protein into an extracellular and an 
intracellular domain (Snider, 1994; Barbacid, 1995). The extracellular domain is important 
for specific NGF binding and includes a signal peptide, three tandem leucine-rich motifs 
flanked by two cysteine clusters, and two immunoglobulin-like domains (or motifs). The 
intracellular domain includes a juxtamembrane region, a tyrosine kinase domain, and a very 
short carboxy-terminal tail (Barbacid, 1995). We found a general correlation between the 
genomic organization of the TRKA gene and the functional organization of TRKA protein. 
Exon 1 contains the signal peptide and the first cysteine cluster. Three leucine-rich motifs are 
encoded by exons 2, 3 and 4, respectively. This suggests that simple duplication can account 
for the variable numbers of the motif. Exon 5 contains the second cysteine cluster. The first 
immunoglobulin-like motif is encoded by exons 6 and 7, while the second immunoglobulin-
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like motif is encoded by the single exon 8. Thus, the splice sites of the TRKA gene encoding 
the extracellular domain separate the functional domains so that each domain is encoded by 
separate exons. Exon 9 is a small (18-bp) one incorporated into mRNA by alternative 
splicing and six amino acid residues encoded by this exon are present in the extracellular 
domain of the neuronal-specific TRKA receptor (Barker et al., 1993). The transmembrane 
domain is encoded by exons 10 and 11 and the intracellular domain of TRKA is encoded by 
exons 11-17. The juxtamembrane domain is encoded by exons 11 and 12. The domain 
contains an IXNPXpY motif where p indicates phosphorylation at Tyr-490 residue of the 
activated TRKA (Dikic et al., 1995). This motif is encoded by exon 12 and is recognized by 
an Shc adaptor protein required for activation of the Ras-MAPK pathway (Obermeier et al., 
1994; Stephens et al., 1994). The tyrosine kinase domain which is phosphorylated in 
response to NGF and is critical for the intercellular signaling is encoded by exons 13-17. A 
consensus sequence motif YXXM which interacts with phosphatidylinositol-3’ kinase, is 
located at the end of the kinase catalytic domain (Tyr-751 residue in TRKA) (Obermeier et 
al., 1993a; Soltoff et al., 1992) and encoded by exon 17. The short carboxy-terminal tail of 
15 amino acids is also encoded by exon 17 and includes a conserved Tyr residue (Tyr-785 in 
TRKA) which is responsible for binding of phospholipase Cγ (Obermeier et al., 1993b; Loeb 
et al., 1994). Thus, the functional domains or motifs are generally encoded by different 
exons, except for exons 10 and 11 which contain a small portion of the transmembrane 
region and a portion of the juxtamembrane region, respectively.  
In addition, there were discrepancies between the nucleotide sequences in exons 7 and 8 
of the genomic clone (T6) and those noted in the cDNA (Martin-Zanca et al., 1989). A single 
base substitution of T-871 to G in exon 7 and substitutions of dinucleotide CG (983 and 984) 
to GC in exon 8 changed codons as follows: Leu-263 to Val and Ser-300 to Cys, respectively. 
We also found these two substitutions in cDNAs from two normal controls and four CIPA 
subjects (data not shown). These amino acid changes were located in the immunoglobulin-
like motifs 1 and 2, respectively. In rat TRKA cDNA, two amino acids corresponding to these 
residues are also Val and Cys, respectively (Meakin et al., 1992). It is noteworthy because 
this immunoglobulin-like motif-2 is the structural element that determines the interaction of 
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neurotrophins with their receptors (Urfer et al., 1995). If our data are accurate, two Cys 
residues should be conserved in the second immunoglobulin-like motif of all human TRK 
family members as in the first immunoglobulin-like motif (Nakagawara et al., 1995). 
The nucleotide sequence of 1226 bp upstream from the base number 1 of the TRKA 
cDNA (Martin-Zanca, et al., 1989) is shown in Fig. 2a. A consensus CAAT or TATA 
elements were not present upstream of the putative region for transcription initiation. To 
determine regulatory sites in the TRKA gene, we used a computer program “TFSEARCH” 
based on a database, “TRANSFAC”, which compiled eukaryotic cis-acting regulatory DNA 
elements and trans-acting factors (Wingender, 1994). Sequences from vertebrates were 
selected on the threshold of 95.0. Sequences similar to the binding site for several 
transcription factors located between -420 and -990. Sequences homologous to the binding 
site for the following proteins were seen in this region: c-Rel /NF-κB (Kunsch et al., 1992; 
Baeuerle and Henkel, 1994; Schmidt et al., 1996) at position -898, AP-2 (Mitchell et al., 
1991; Faisst and Meyer, 1992) at position -852, CdxA (Margalit et al., 1993; Frumkin et al., 
1993) at position -809, CCAAT displacement protein (CDP-CR) (Neufeld et al., 1992; 
Harada et al., 1995) at position -767, and heat shock transcription factor (HSF) at position -
429 (both directions) (Kroeger and Morimoto, 1994). Determination of the precise putative 
promoter sites in transcriptional regulation of the TRKA gene is the subject of ongoing study. 
The nucleotide sequence of the 3’ exon region of the gene is shown in Fig. 2b. The site of the 
polyadenylation signal was inferred from the cDNA. A noncanonical polyadenylation signal 
was present 21 bases upstream of the polyadenine tail. 
Oncogenic rearrangements often involve the same region of the TRKA gene, resulting in 
the same junction. Our study indicates that the region frequently involved in the 
rearrangements is located in exons 8 through 12 of the TRKA. The structural and genomic 
organization of the whole human TRKA gene will provide a basis for elucidation of 
mechanisms responsible for such rearrangement(s). In addition, we found a microsatellite 
region (GT or CA repeat) located in intron 12. The nucleotide sequence flanking this locus 
was reported (Greco et al., 1993) and discussed (Butti et al., 1995). Position of this locus 
(AFMa127wh9) and data on the heterozygosity were described (Dib et al., 1996).  
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Clinically, CIPA is a serious illness that might be fatal in the first years of life if the 
hyperpyrexia is not properly overcome. In older children, osteomyelitis and bone and/or joint 
deformities demand surgical procedures sometimes involving extensive amputations (Dyck, 
1984; McKusick, 1994). To data, three different mutations in four families have been 
identified. A deletion-, a splice- and a missense-mutations all in the region encoding the 
tyrosine kinase domain were detected in these families. The present study revealed that a 
single base deletion and missense mutations are located in exon 14 of this gene. Splice 
mutation is located in the 5’-splice donor site of intron 15. This study will facilitate analyses 
of CIPA mutations in other regions of TRKA. Identification of such mutations will further 
genetic diagnoses of this painless but serious disease. 
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Fig. 1. Physical map of the human TRKA gene.  
The structure of the gene is shown by a thick line. Exons 1-17 are shown as vertical lines and 
numbered. Below the gene structure, the genomic DNA fragments from the phage clones are 
shown by dotted lines. BamHI and SacI sites are shown above. 
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Fig. 2. Nucleotide sequences of the 5’ and 3’ regions of the human TRKA gene.  
(a) Nucleotide sequence of the 5’ region of the gene.  
The sequence is numbered according to Martin-Zanca et al (Martin-Zanca et al., 1989), 
starting from guanine at base number 1 of the cDNA. Sequences with a horizontal arrow 
indicate the putative region resembling binding sites for specific transcription factors. The 
directions of the sequence are indicated by the directions of the arrows. The translation start 
codon ATG is underlined.  
(b) Nucleotide sequences of the 3’ region of the gene.  
The termination codon, TAG, is marked (***). The sequence is numbered starting from 
thymidine of the termination codon. A vertical arrowhead indicates the poly(A) addition site. 





Table 1  
Exon-Intron Organization of the human TRKA gene 
 Size cDNA  Size     






    













  C TAC 
Leu Tyr 
 2  75 297-371  2 0.3 AAC CT 
Asn Leu 
gtgagggaaacggggactgt ..... cctcctgcacccctccccag   C ACC 
Leu Thr 
 3  72 372-443  3 2.1 CGC CT 
Arg Leu 
gtgagtgtggccagtgctgg ..... ctgtgtctccacgcccgcag   G AAT 
Leu Asn 
 4  69 444-512  4 1.2 GAA CT 
Glu Leu 
gtgagtgggggcgcttccag ..... gtgtcccccatgccccccag   G GTC 
Leu Val 
 5 146 513-658  5 0.3 TGT G 
Cys Gly 
gtaggtgccgggtgagggag ..... cgggcgtcctgggtggccag  GT GTG 
Gly GTG 
 6 143 659-801  6 2.3 GTG ATG 
Val Met 
gtgagaagaccttcgctggc ..... ccctctctttcctgatctag AAA TCT 
Lys Ser 
 7 133 802-934  7 2.1 TCC T 
Ser Phe 
gtgagtctcagtggcagctc ..... ttgctctttctggcccacag  TC CCG 
Phe Pro 
 8 327  935-1261  8 0.4 CCT G 
Pro Val 
gtgcgagggccatcctgaac ..... tctcctccctcctgctgcag  TC TCC 
Val Ser 
 9b  18 -  9 0.2 GTG G 
Val Asp 
gtgagtagcccaaggtggag ..... cctgccctgtgtccctacag  AC ACT 
Asp Thr 
10  56 1262-1317 10 0.3 TTT GGG 
Phe Gly 
gtgagataggaagtagaagc ..... ctacccctgtcccccaccag GTC TCG 
Val Ser 
11 103 1318-1420 11 0.5 AAC C 
Asn Arg 
gtgagtcggggctgcagaggg ..... cggctgtgtctcctctctag  GC CCG 
Arg Pro 
12 147 1421-1567 12 0.4 GCC T 
Ala Cys 
gtgaggggctatgctgggtc ..... gaccctgcaagccccctcag  GT GTT 
Cys Val 
13 131 1568-1698 13 0.2 GTC AAG 
Val Lys 
gtgagaccctgccccggggg ..... tccctgccgcttccatccag GCA CTG 
Ala Leu 
14 173 1699-1871 14 2.5 CTC CG 
Leu Arg 
gtaccagcacctggcctcag ..... tctccttttcttgttcacag   A TCC 
Arg Ser 
15 241 1872-2112 15 0.7 TAC CGT 
Tyr Arg 
gtaagggtcctttgtcccca ..... gcagtgtccgcccgtggcag GTG GGA 
Val Gly 
16 159 2113-2271 16 1.2 ACG GAG 
Thr Glu 
gtcagccccggcccatggtc ..... tgtctctccggtggccccag GCA ATC 
Ala Ile 
17 394 2272-2665   CTT G 
 
   
a Numbered according to Martin-Zanca et al. (1986). 
b A small exon incorporated into mRNA of neural tissues by alternative splicing (Barker et al., 1993). 
